Eisler Capital (UK)’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-310,294
Closed -$3.07M 398
2022
Q2
$3.07M Buy
310,294
+71,953
+30% +$711K 0.1% 136
2022
Q1
$2.35M Buy
238,341
+5,741
+2% +$56.4K 0.04% 266
2021
Q4
$2.27M Buy
+232,600
New +$2.28M 0.11% 140

Other funds holding EUCR

Eisler Capital (UK)'s EUCR Position: Q3 2022 in Review

Eisler Capital (UK) sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q3 2022, closing a stake of 310,294 shares — an estimated $3.07M sold.

Eisler Capital (UK) first reported a position in EUCR in Q4 2021 and held it in 3 quarters. The position peaked at $3.07M in Q2 2022. 38 funds tracked by Wall St. Rank hold EUCR as of Q3 2022.

  • Eisler Capital (UK) reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Eisler Capital (UK) sold 310,294 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q3 2022, an estimated $3.07M.
  • Eisler Capital (UK) first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 3 quarters.
  • Eisler Capital (UK)'s Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $3.07M in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q3 2022.

Based on Eisler Capital (UK)'s 13F filing for Q3 2022, filed 14 Nov 2022.